NASDAQ$IGMS

IGM Biosciences Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Headline financials

Total Revenue

$448K

Previous: $366K+22.4%
EPS (adj)

-$1.43

Previous: -$1.33-7.5%
Research and Development Expenses

$55.7M

No prior period
General and Administrative Expenses

$13M

No prior period
Capital Expenditures

$3.91M

Previous: $1.82M+114.6%
Free Cash Flow

-$57M

Previous: $109M-152.1%
Net Income

-$64.4M

Previous: -$58M-11.1%
Operating Income

-$68.2M

Previous: -$59.2M-15.2%
Cash & Equivalents

$151M

Previous: $221M-31.9%
Total Assets

$481M

Previous: $582M-17.4%
Stock-Based Comp

$14.3M

Previous: $11.3M+26.8%

Revenue & EPS history

IGM Biosciences · Revenue · Quarterly

$448K

Q2 2023+22.4%vs Q2 2022
Beat estimate in 5 of 13 quarters(38%)
ActualEstimate

Revenue by segment

IGM Biosciences · $400K total across 1 segment · Q2 2023

  • Collaboration Revenue
    $400K

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

+4.2%

Avg return

Earnings day

-6.5%

Avg return

5 days after

-4.3%

Avg return

30 days after

58%

14 / 24 earnings

Positive

+72.4%

Q4 2021

Best reaction

-20.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025
Q2 2025+0.0%+0.8%
Q1 2025+4.2%+1.7%+3.4%
Q4 2024-2.4%-8.0%+5.6%
Q3 2024-10.4%-21.9%-27.9%
Q2 2024+4.4%+7.8%+38.5%
Q1 2024+1.9%-7.2%-17.3%
Q4 2023+2.4%-18.5%-28.1%
Q3 2023+7.3%
Q2 2023-7.1%
Q1 2023+6.7%
Q4 2022-20.4%
Q3 2022-9.9%
Q2 2022+22.2%
Q1 2022-7.5%
Q4 2021+72.4%
Q3 2021+15.9%
Q2 2021+8.9%
Q1 2021+10.9%
Q4 2020+4.1%
Q3 2020-4.2%
Q2 2020-4.2%
Q1 2020+5.6%
Q4 2019-1.8%
Q3 2019+1.2%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro